- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05706831
Intervenção Musical e Estimulação Elétrica Transcraniana para Doenças Neurológicas
Intervenção Musical e Estimulação Elétrica Transcraniana no Tratamento de Doenças Neurológicas
The goal of this clinical trial is to evaluate the efficacy of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are:
- to evaluate the residual neuroplastic processes in DOC state related to music exposure
- to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation
- to evaluate the impact of this intervention on caregiver's burden and psychological distress.
Participants will be randomly assigned to one of three different music-listening intervention groups. Primary outcomes will be clinical, that is based on the neurologist's observations of clinical improvement, and neurophysiological, collected pre-intervention, post-intervention and post-placebo.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Simona Spaccavento
- Número de telefone: +393332783524
- E-mail: simona.spaccavento@icsmaugeri.it
Locais de estudo
-
-
Ba
-
Bari, Ba, Itália, 70025
- Recrutamento
- Istituti Clinici Scientifici Maugeri
-
Contato:
- Simona Spaccavento
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age > 18 years
- Post-stroke aphasia
- Post-stroke neglect
- Patients with disorders of consciusness (DOC)
Exclusion Criteria:
- No auditory injury
- no hystory of neurological disease
- No hystory of psychiatric disease
- Previous stroke
- use of alcohol and drugs
- premorbid dementia
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Group 1
Group 1 will receive tEs combined with music stimulation for 2 weeks, 1 week of wash out, then sham stimulation combined with noise (placebo) for other 2 weeks. |
music |
|
Experimental: Group 2
Group 2 will receive sham stimulation and noise (placebo) for the first 2 weeks, then 1 week wash out, and finally tEs and music stimulation for other 2 weeks. |
music |
|
Experimental: Group 3
Group 3 will receive only music stimulation and sham stimulation for 2 weeks, 1 week of wash out, then sham stimulation and noise (placebo) for another 2 weeks. |
music |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Neuropsychological outcomes
Prazo: Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
-Coma Recovery Scale-Revised (CRS-R) - (0-23). High score means a better outcome. |
Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
Disability Rating Scale (DRS) - (0-29). High score means a worse outcome. |
Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
Rancho Levels of Cognitive Functioning (LCF) - (1-8). High score means a better outcome. |
Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
Glasgow Outcome Scale- Extended (GOS-E) - (1-8). High score means a better outcome. |
Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
Aachener Aphasie Test (AAT). This test includes six subtests: spontaneous speech, token test, repetition, written language, naming, and comprehension. Spontaneous speech is structured in six parts (0-30). High score means a better performance; Token test is composed by 50 items; for the score the number of error id considered (0-50). Repetition sub test is composed by 50 items; for each item the score range from 0 to 3; high score means better outcome (0-150). Written language subtest is composed by 30 items; for each item the score range from 0 to 3; high score means better outcome (0-90). Naming subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). Comprehension subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). |
Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
Italian version of Functional Outcome Questionnaire for Aphasie (FOQ-A) - (32-160). High score means a better outcome. |
Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
Functional Assessment Measure - Cognitive subscale - (FAM) - (14-98); high score means a better outcome. |
Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
Quality of Life questionnaire for Aphasics (QLQA) - (0-148); High score means a better outcome. |
Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
The semi-structured scale for functional evaluation of personal neglect - (0-9); High score means a worse outcome. |
Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Barrage Test at 2 weeks and 4 weeks
|
Barrage test (0-36). High score means a better outcome. |
Change from baseline Barrage Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
Letter cancellation test - (0-104). High score means a better outcome. |
Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
Sentence reading test (0-6). High score means a worse outcome. |
Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
Wundt-Jastrow area illusion test (0-20). High score means a worse outcome. |
Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Prazo: Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
The semi structured scale for the functional evaluation of extrapersonal neglect (0-9). High score means a worse outcome. |
Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
|
Neurophysiological outcome
Prazo: Change from baseline oscillation at 2 weeks and 4 weeks
|
The ratio of fast (8-30 Hz, α-β) to slow (2-8 Hz, δ-θ) oscillation amplitude at the midline electrodes (Fz, Cz, Pz, Oz) will be measured and compared pre- and post intervention." |
Change from baseline oscillation at 2 weeks and 4 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Caregiver psychological distress
Prazo: Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
Back depression Inventory II (BDI II) - (0-63). High score means a worse outcome. |
Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Prazo: Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
State-trait anxiety inventory (STAI-Y). It is composed by two scales: STAI-Y State (20-80) and STAI-Y Trait (20-80). High score means a worse outcome. |
Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Prazo: Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
Psychophysiological Questionnaire (30-120). WHOQOL-BREF. |
Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Prazo: Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
Prolonged grief disorder -12 (PG-12) - (11-55). High score means a worse outcome. |
Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Prazo: Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
Family strain questionnaire (FSQ) - (1-44). High score means a worse outcome. |
Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Prazo: Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
better outcome. |
Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Transtornos Mentais, Desordem Mental
- Manifestações Neurocomportamentais
- Distúrbios Neurocognitivos
- Distúrbios da Comunicação
- Distúrbios de Linguagem
- Distúrbios da fala
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Derrame
- Afasia
- Distúrbios da Consciência
Outros números de identificação do estudo
- 345
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .